Press release
Global Biosimilar & Biosuperior Therapeutic Antibodies Industry : Insights, Development, Research and Forecast 2017-2021
ALBANY, NY, May 17, 2017 : ResearchMoz presents professional and in-depth study of "Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies - 2016 Update".This Competitive Intelligence report about Biosimilar & Biosuperior Therapeutic Antibodies updates the competitive landscape of biosimilar therapeutic antibodies as of May 2016. The report evaluates the the first wave of biosimilar recombinant monoclonal antibodies in comparison with the corresponding originator antibodies and biosuperior antibodies against the same target. The report also describes the next wave of potential biosimilar versions of therapeutic antibodies loosing patent protection in the time frame of 2019 – 2023. The report specifically lists for each target the branded products with their 2015 sales and up-side indications in development, as well as biosuperior and biosimilar antibody drug candidates in development.
Get PDF for more Professional and Technical insights @ http://www.researchmoz.us/enquiry.php?type=S&repid=724046
The report includes a compilation of marketed, approved and currently active projects in research and development of biosimilar and biosuperior therapeutic antibodies against commercially and clinically validated targets relevant for the first wave of biosimilar antibodies (VEGF, TNF, Her2, CD20, EGF-R). Relevant first wave originator therapeutic antibodies are Humira, Enbrel, Remicade, Avastin, Lucentis, Eylea, Herceptin, Rituxan/MabThera and Erbitux. Second generation therapeutic antibodies against these targets such as Symponi, Cimzia, Cyramza, Perjeta, Arrzera are also subject of biosimilar activities.
The report also addresses the slowly emerging second wave of biosimilar antibody activities against originator therapeutic antibodies such as abatacept, alemtuzumab, denosumab, eculizumab, omalizumab, pavilizumab, tocilizumab, and ustekinumab.
Competitor projects are listed in a tabular format providing information on:
Drug Codes,
Target/Mechanism of Action,
Class of Compound,
Company,
Product Category,
Indication,
R&D Stage and
additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Table of Content
A) 2015 SALES OF THERAPEUTIC ANTIBODIES
Overview: 2015 Biologics Sales per Class of Products
Overview: 2015 Therapeutic Antibody Sales per Class of Products
Blockbuster Therapeutic Antibodies in 2015
Anti-TNF Antibody Sales in 2015
Cancer Antibody Sales in 2015
Other Anti-Inflammatory Antibody Sales in 2015
Ophthalmic Antibody Sales in 2015
Cardiometabolic & Anti-Infective Antibody Sales in 2015
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=724046
B) BIOSIMILAR AND BIOSUPERIOR ANTI-TNF ANTIBODIES – 2016 UPDATE
1. Originator Anti-TNF Antibodies
Approved and Marketed Indications of anti-TNF Antibodies in Regulated Markets
2015 SALES OF ANTI-TNF ANTIBODIES
Sales of Anti-TNF Antibodies in Q1/2016
Humira Pipeline of Recently Approved Indications & Upside Developments
Remicade Pipeline of Recent Approvals & Upside Indications
Enbrel Pipeline of Upside Indications
Simponi Pipeline of Recent Approvals & Upside Indications
Cimzia Pipeline of Recent Approvals & Upside Indications
Defense Strategies against Biosimilar Anti-TNF Antibodies
2. Biosuperior Anti-TNF Antibodies
Non-Antibody Anti-TNF Biosuperiors
Anti-TNF Biosuperior Antibodies
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
ResearchMoz
90 State Street,
Albany, NY 12207,
United States
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Biosimilar & Biosuperior Therapeutic Antibodies Industry : Insights, Development, Research and Forecast 2017-2021 here
News-ID: 540526 • Views: …
More Releases from Biotechnology
Global Biotechnology Market Report 2019 Companies included Roche, Pfizer, Merck, …
#7th Edition Biotechnology market report recently has been published by market reports company. It features comprehensive market outlook based on historic data from 2013 to 2018 and estimated market trends during the forecast period from 2018 to 2026.
To access complete insights of global Biotechnology market report: sales@marketreportscompany.com
The Biotechnology market delivers a wide array of primary and secondary data with respect to regional and global market. In-depth analysis of numerous…
Epigenetics Market by End Users, and by Geography North America, Latin America, …
Increasing research to study the epigenetics of the genome (study called epigenomics) is expected to boost growth of the epigenetics market over the forecast period. Genome-wide epigenetic studies play an important role in the diagnostics of human diseases. Moreover, implementation of epigenetics for oncology research is estimated to propel the growth of epigenetics market. For instance, Constellation Pharmaceuticals, in April 2018, invested US$ 100 million for development of cancer epigenetics…
Industrial Microbiology–Solving Big Issues with Micro Size/Microbial Revolutio …
Advances in fields of Recombinant DNA technology, use of microorganisms in treating diseases, rising prevalence of various bacterial, and viral infections globally is expected to boost the growth of industrial microbiology market with respect to pharmaceutical industry. Use of microorganisms in manufacturing various improvised vaccines for existing as well new infectious diseases is supporting the market growth. Cosmetic industry is growing, owing to the factors, such as evolving lifestyles, increasing…
Soft Tissue Repair Market, by Product Type Fixation Products, Tissue Patch,
According to the European Union government legislature, European government will be spending almost 80 billion Euros on Research and Development to enhance a broad range of research projects. According to American Joint Replacement Registry (AJRR), around 75% increase in hospitals was reported and 41% increase in the number of surgeons from the year 2012 -2015, hence there is an increment of 102% in the number of cases related to joint…
More Releases for TNF
The Prevalence Of Inflammatory Diseases Driving Tnf Alpha Inhibitor Market Growt …
The TNF Alpha Inhibitors Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the TNF Alpha Inhibitors Market?
The TNF alpha inhibitors market has seen modest growth in recent years. It is expected to increase from $43.09 billion in 2024 to…
The Prevalence Of Inflammatory Diseases Driving Tnf Alpha Inhibitor Market Growt …
The TNF Alpha Inhibitors Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the TNF Alpha Inhibitors Market?
The TNF alpha inhibitors market has seen modest growth in recent years. It is expected to increase from $43.09 billion in 2024 to…
Transforming the TNF Alpha Inhibitors Market in 2025: The Prevalence Of Inflamma …
What Is the Expected Size and Growth Rate of the TNF Alpha Inhibitors Market?
There has been a slight increase in the size of the TNF alpha inhibitors market in the recent past. Projected growth of this market is from $43.09 billion in 2024, rising to $43.57 billion in 2025, indicating a compound annual growth rate of 1.1%. The historic period's growth can be tied to a combination of factors, such…
Transforming the TNF Alpha Inhibitors Market in 2025: The Prevalence Of Inflamma …
What Is the Expected Size and Growth Rate of the TNF Alpha Inhibitors Market?
There has been a slight increase in the size of the TNF alpha inhibitors market in the recent past. Projected growth of this market is from $43.09 billion in 2024, rising to $43.57 billion in 2025, indicating a compound annual growth rate of 1.1%. The historic period's growth can be tied to a combination of factors, such…
Introduction to Tumor Necrosis Factor (TNF) Inhibitors
Tumor Necrosis Factor (TNF) inhibitors are a class of medications that have revolutionized the treatment of autoimmune diseases and inflammatory conditions. TNF is a cytokine, a protein involved in immune system signaling, that plays a central role in the inflammatory response. While TNF is essential for fighting infections and controlling immune reactions, excessive or uncontrolled TNF activity can lead to chronic inflammation, contributing to various autoimmune diseases such as rheumatoid…
TNF Inhibitors Market to Witness an Outstanding Growth by 2030
The TNF Inhibitors Market 2024 Report makes available the current and future technical and financial analysis of the industry. It is one of the most comprehensive and important additions to the USD Analytics archive of market research studies. It offers detailed research and analysis of key aspects of the global TNF Inhibitors market. This global report explores the key factors affecting the growth of the dynamic TNF Inhibitors market, including…
